Key result
The dominant EDN2 A allele was associated with an increased risk of atrial fibrillation in patients with hypertrophic cardiomyopathy (allele prevalence 42.3% in AF vs 16.7% in sinus rhythm; p=0.014).
Why the study?
Does the EDN2 A985G polymorphism increase the risk of atrial fibrillation in patients with hypertrophic cardiomyopathy?
Population
110 patients with hypertrophic cardiomyopathy who had no clinically documented atrial fibrillation before…
Comparison
Presence of the endothelin-2 A985G polymorphism vs Absence of the EDN2 A allele (G/G genotype)
Design
Cohort
Follow-up
mean 13±7 years
Authors
Loading...
EDN2 A allele may flag higher AF risk in HCM; leaves open whether genotyping aids stratification before prospective validation.
Cohort (n=110)
Does the EDN2 A985G polymorphism increase the risk of atrial fibrillation in patients with hypertrophic cardiomyopathy?
Absolute Event Rate: 42.3% vs 16.7%
p-value: p=0.014
The EDN2 A985 allele, along with the ACE insertion/insertion genotype and increased QRS dispersion, is an independent risk factor for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy.
Nagai et al. (2007) conducted a cohort in Hypertrophic cardiomyopathy (n=110). EDN2 A985G polymorphism (dominant EDN2 A allele) vs. No dominant EDN2 A allele was evaluated on Occurrence of atrial fibrillation (p=0.014). The dominant EDN2 A allele was associated with an increased risk of atrial fibrillation in patients with hypertrophic cardiomyopathy (allele prevalence 42.3% in AF vs 16.7% in sinus rhythm; p=0.014).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: